NCT02658214 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT02658214
Title	Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors
Recruitment	Completed
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	AstraZeneca
Indications	peritoneum cancer fallopian tube cancer ovarian cancer triple-receptor negative breast cancer stomach cancer lung small cell carcinoma gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma
Therapies	Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab
Age Groups:	adult \| senior
Covered Countries

Facility	City	Zip	Country	Details
Research Site	Chūōku	104-0045	Japan	Details
Research Site	Kashiwa	277-8577	Japan	Details
Research Site	Seoul	03080	South Korea	Details
Research Site	Seoul	03722	South Korea	Details
Research Site	Seoul	05505	South Korea	Details
Research Site	Seoul	135-710	South Korea	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT02658214Clinical Trial Detail